Fig. 7From: Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysisRelative risk in patients with rheumatologic PAD receiving anti-rheumatic treatment at the start of ICI therapy compared with those not receiving treatment: (A) flare; (B) new-onset irAEs; (C) ORR; (D) DCR. ORR: objective response rate; DCR: disease control rateBack to article page